AN2 Therapeutics Inc./$ANTX
1D1W1MYTD1Y5YMAX
Capital at risk
About AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
- Ticker
- $ANTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Menlo Park, United States
- Website
- www.an2therapeutics.com
ANTX Metrics
BasicAdvanced
$206M
-
-$1.04
-0.99
-
Price and volume
Market cap
$206M
Beta
-0.99
52-week high
$7.19
52-week low
$1.00
Average daily volume
219K
Financial strength
Current ratio
14.322
Quick ratio
14.089
Profitability
Management effectiveness
Return on assets (TTM)
-30.80%
Return on equity (TTM)
-50.12%
Valuation
Price to book
2.61
Price to tangible book (TTM)
2.61
Price to free cash flow (TTM)
-6.207
Free cash flow yield (TTM)
-16.11%
Free cash flow per share (TTM)
-0.88
Growth
Earnings per share change (TTM)
-16.56%
3-year earnings per share growth (CAGR)
-28.07%
Upcoming events
No upcoming events
ANTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.